🔎 Trials Near Me

Acasă › Limfom Burkitt › Maryland

Studii clinice pentru Limfom Burkitt în Maryland

11 studii pentru Limfom Burkitt caută participanți în Maryland.

Orașe în Maryland

Text oficial al studiului (în engleză)

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
În curs de recrutareFaza 2
366 Days – 46 Years · Toate sexele · Actualizat 2 oct. 2026 · NCT06124157

Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

  • University of Maryland/Greenebaum Cancer Center, Baltimore
În curs de recrutareFaza 3
Vârste de la 18 la 39 · Toate sexele · Actualizat 2 oct. 2026 · NCT03150693

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies

  • National Institutes of Health Clinical Center, Bethesda
În curs de recrutareFaza 1/2
Vârste de la 3 la 39 · Toate sexele · Actualizat 30 sept. 2026 · NCT05442515

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

  • National Institutes of Health Clinical Center, Bethesda
În curs de recrutareFaza 1/2
Vârste de la 18 la 120 · Toate sexele · Actualizat 28 sept. 2026 · NCT03223610

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
În curs de recrutareFaza 2
365 Days · Toate sexele · Actualizat 25 sept. 2026 · NCT06317662

Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies

  • Johns Hopkins Asthma & Allergy Center, Baltimore
  • American Oncology Partners, PA dba The Center for Cancer and Blood Disorders, Bethesda
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 21 sept. 2026 · NCT07648264

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

  • University of Maryland, Baltimore
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 8 sept. 2026 · NCT03666000

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
În curs de recrutareFaza 2
Vârste de la 1 la 30 · Toate sexele · Actualizat 1 sept. 2026 · NCT04546399

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

  • National Institutes of Health Clinical Center, Bethesda
În curs de recrutareFaza 1
Vârste de la 18 la 120 · Toate sexele · Actualizat 25 aug. 2026 · NCT05389423

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

  • University of Maryland/Greenebaum Cancer Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
  • și încă 1
În curs de recrutareFaza 3
365 Days – 25 Years · Toate sexele · Actualizat 25 aug. 2026 · NCT03959085

Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL

  • University of Maryland, Baltimore
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 5 nov. 2025 · NCT04260022

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.